Doorgaan naar hoofdnavigatie
Doorgaan naar zoeken
Ga verder naar hoofdinhoud
Sorteer per
Medicine and Dentistry
Biological Marker
44%
Blood Brain Barrier
6%
Cell Cycle
5%
Cell Cycle Regulation
5%
Cell-Free DNA
41%
Cerebrospinal Fluid
5%
Childhood Cancer
5%
CHRNA3
5%
Clinical Study
6%
Disseminated Disease
16%
Droplet Digital Polymerase Chain Reaction
38%
Event Free Survival
13%
Ewing Sarcoma
8%
Fusion Gene
9%
Ganglioneuroblastoma
46%
In Vitro
6%
Intracranial Tumor
20%
Invasive Diagnostics
5%
Kidney Tumour
5%
Liquid Biopsy
91%
Localized Disease
5%
Malignant Neoplasm
10%
Messenger RNA
21%
Metastatic Carcinoma
13%
Minimal Residual Disease
7%
Neoplasm
53%
Nucleic Acid
5%
Patient with Neuroblastoma
24%
Pediatric Cancer
10%
Pediatrics
100%
Pediatrics Patient
20%
Platelet
5%
Real-Time Polymerase Chain Reaction
10%
Reduced Representation Bisulfite Sequencing
8%
Rhabdomyosarcoma
47%
Risk Stratification
16%
RNA Directed DNA Polymerase
10%
Size-Exclusion Chromatography
10%
Solid Malignant Neoplasm
81%
Specific Tumor
6%
Systematic Review
18%
Thrombocyte Poor Plasma
5%
Tumor Marker
15%
Whole Genome Sequencing
5%
Wilms' Tumor
8%
Keyphrases
Blood-brain Barrier
8%
Bone Marrow
10%
Brain Tumor
9%
Brain Tumor Patients
16%
Cell-free DNA (cfDNA)
34%
Cell-free RNA
16%
Clinical Potential
16%
Confidence Interval
13%
Diagnostic Biomarker
17%
Diagnostic Potential
5%
Diagnostic Tool
16%
Disseminated Infection
16%
Droplet Digital PCR (ddPCR)
32%
Event-free Survival
10%
Ewing Sarcoma
8%
Extracellular Vesicles
29%
Focused Ultrasound
16%
Fusion Gene
9%
Healthy Controls
6%
Liquid Biopsy
87%
Material Reference
16%
Metastatic Disease
8%
Minimally Invasive
5%
Molecular Detection
16%
Multiplex
6%
Neuroblastoma
31%
Patient-specific
16%
PCR Assay
6%
Pediatric Patients
19%
Pediatric Rhabdomyosarcoma
16%
Pediatric Tumors
81%
Peripheral Blood
7%
Plasma Samples
9%
Primary Brain Tumor
5%
Prognostic Biomarker
19%
Quantitative PCR
14%
RASSF1A
32%
Region of Interest
6%
Reverse Transcriptase
10%
Rhabdomyosarcoma
34%
Risk Stratification
16%
Size Exclusion Chromatography
6%
Specific Marker
12%
Targeted Locus Amplification
16%
Technical Potential
16%
Tumor
23%
Tumor Biomarkers
8%
Tumor-specific
6%
Ultrasound-enhanced
16%
Working Diagnosis
10%
